content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Northwest Biotherapeutics, Inc. (NWBO)

0.18
-0.00
(-0.56%)
Sep 11, 3:57PM EDT
content_middle

Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Its DCVax uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company develops DCVax-L, which is under Phase III clinical trials for glioblastoma multiforme brain cancer and ovarian cancer, and for other cancers in situations, which the patient has their tumor surgically removed as part of standard of care; DCVax-Direct that is under Phase I/II clinical for solid tumor cancers; and DCVax-Prostate, which is under Phase III clinical trial for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Previous Close: 
0.18
Open: 
0.18
Bid: 
N/A
Ask: 
N/A
1yr Target Price: 
5.00
Day's Range: 
0.18 - 0.18
52wk Range: 
0.14 - 0.98
Volume: 
687296
Average Daily Volume: 
2060790
Market Capitalization: 
52.85M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
295253000M
content_right

Pages